Search Results

Showing results 9751 - 9760 for 2023

Contact Us Form| Primary Care Innovation

...Funding Opportunities (RFPs)Toggle Funding Opportunities (RFPs) menu options Request for Proposals 2022-2023...

https://careinnovation.weill.cornell.edu/contact-us-0

On May 27 2020, Dr. Daniel Heller was recognized with the 2020 Outstanding Teaching and Mentoring Award from the Weill Cornell Graduate School. | Pharmacology

...-2024 Seminar Archives 2022-2023 Seminar Archives 2021-2022 Seminar Archives 2020-2021 Seminar Archives...

https://pharmacology.weill.cornell.edu/about-us/news/may-27-2020-dr-daniel-heller-was-recognized-2020-outstanding-teaching-and-mentoring

Schnappinger, Dirk

...drug discovery (INV-004761)  awarded by Bill & Melinda Gates Foundation Principal Investigator 2020 - 2023...

http://vivo.med.cornell.edu/display/cwid-dis2003

Retreat 2022: Bushkill Inn - Bushkill Falls, PA | Pharmacology

...-2024 Seminar Archives 2022-2023 Seminar Archives 2021-2022 Seminar Archives 2020-2021 Seminar Archives...

https://pharmacology.weill.cornell.edu/students/parties-and-events/retreat-2022-bushkill-inn-bushkill-falls-pa

Dr. Rohan Jotwani Named Editor-in-Chief | Department of Anesthesiology

...Established in 2023, it is the official journal of the American Medical Extended Reality Association...

https://anesthesiology.weill.cornell.edu/news/dr-rohan-jotwani-named-editor-in-chief

What are Patient Reported Outcomes ( PRO)s? | Weill Cornell Medicine Multiple Sclerosis Center

...January 4, 2023 Share to Facebook Share to Twitter Share to LinkedIn Share on Email Patient Reported...

https://mscenter.weillcornell.org/news-and-updates/what-are-patient-reported-outcomes-pros

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). | Shah Lab

...Submitted by qub4002 on July 10, 2023 - 4:25pm Title Phase III Study to Evaluate Efficacy and Safety...

https://shahlab.weill.cornell.edu/publications/phase-iii-study-evaluate-efficacy-and-safety-andecaliximab-mfolfox6-first-line

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | Shah Lab

...Submitted by qub4002 on July 10, 2023 - 3:50pm Title Randomized, Double-Blind, Placebo-Controlled...

https://shahlab.weill.cornell.edu/publications/randomized-double-blind-placebo-controlled-phase-iii-study-paclitaxel-%C2%B1-napabucasin

11.11 - Requirements for Securing Systems | Information Technologies & Services

...Last reviewed: September 12, 2023 Policy Statement Weill Cornell Medicine mandates that its information...

https://its.weill.cornell.edu/policies/1111-requirements-for-securing-systems

A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer | Research | Weill Cornell Medicine

...Research A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer August 23, 2023...

https://research.weill.cornell.edu/about-us/news-updates/new-targeted-treatment-shows-promise-select-patients-stomach-cancer

Showing results 9751 - 9760 for 2023